Jean Scott and Peter Illingworth Richard Anderson Anna Pia Ferraretti More Boys from IVF compared to ICSI REFERENCE: Abstract O-41 Jean Scott, IVF Australia, Hunters Hill, New South Wales; Peter Illin

Jean Scott and Peter Illingworth

Richard Anderson

Anna Pia Ferraretti
More Boys from IVF compared to ICSI
REFERENCE: Abstract O-41Jean Scott, IVF Australia, Hunters Hill, New South Wales; Peter Illingworth, Medical Director of IVF AustraliaIn vitro fertilisation results in a higher proportion of boys compared to intra-cytoplasmic sperm injection – that’s according to data presented byJean Scottof IVF Australia. Together with IVF Australia’s medical director,Peter Illlingworth, she describes the data and discusses the implications.
Cancer Chemotherapy and Female Fertility: Taxanes May Increase Damage to Ovarian Function
REFERENCE: Abstract O-122Richard Anderson, Queen’s Medical Research Institute, University of EdinburghA premenopausal woman with breast cancer, who is about to take chemotherapy, may want to do everything possible to preserve her fertility. Data presented byRichard Andersonof Edinburgh University suggest that regimens involving taxanes may increase the damage to her ovaries.
New Technique for Detecting Egg Defects Before Fertilisation
REFERENCE: Abstract O-13Anna Pia Ferraretti, S.I.S.M.E.R. Clinic, BolognaResearchers from Italy have revealed a technique which allows them to spot certain defects in an egg cell before it is used for insemination.Anna Pia Ferraretti, of the S.I.S.M.E.R. Clinic in Bologna, had the details in Prague.
Tags
Related Episodes

Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema
Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema An interview with: Amparo Garcia-Tejedor MD, PhD, Profe

Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer
Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer An interview with: Eline Verreck BSc, Erasmus University Medical Centre, Surgical Oncology Department, Rotterd

Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer
